DOP2012000284A - Heterociclilbencilpirazoles sustituidos y uso de los mismos - Google Patents

Heterociclilbencilpirazoles sustituidos y uso de los mismos

Info

Publication number
DOP2012000284A
DOP2012000284A DO2012000284A DO2012000284A DOP2012000284A DO P2012000284 A DOP2012000284 A DO P2012000284A DO 2012000284 A DO2012000284 A DO 2012000284A DO 2012000284 A DO2012000284 A DO 2012000284A DO P2012000284 A DOP2012000284 A DO P2012000284A
Authority
DO
Dominican Republic
Prior art keywords
diseases
prevention
treatment
heterociclilbencilpirazoles
replaced
Prior art date
Application number
DO2012000284A
Other languages
English (en)
Inventor
Peter Ellinghaus
Hartmut Beck
Michael Harter
Joachim Schuhmacher
Susanne Greschat-Schade
Kerstin Unterschemman
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000284(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of DOP2012000284A publication Critical patent/DOP2012000284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a derivados de 1-[3-(heterociclil)bencil]-1H-pirazol novedosos, a procedimientos para su preparación, a su uso para el tratamiento yio la prevención de enfermedades y a su uso para la producción de medicamentos para el tratamiento yio la prevención de enfermedades, más particularmente para el tratamiento yio la prevención de enfermedades hiperproliferativas y angiogénicas y las enfermedades que se originan de la adaptación metabólica a estados hipóxicos. Tales tratamientos se pueden llevar a cabo en forma de monoterapia o también en combinación con otros medicamentos o medidas terapéuticas adicionales.
DO2012000284A 2010-05-08 2012-11-07 Heterociclilbencilpirazoles sustituidos y uso de los mismos DOP2012000284A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10004855 2010-05-08

Publications (1)

Publication Number Publication Date
DOP2012000284A true DOP2012000284A (es) 2013-03-31

Family

ID=44063276

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000284A DOP2012000284A (es) 2010-05-08 2012-11-07 Heterociclilbencilpirazoles sustituidos y uso de los mismos

Country Status (25)

Country Link
US (2) US20130172311A1 (es)
EP (1) EP2569312B1 (es)
JP (1) JP5727002B2 (es)
KR (1) KR20130108997A (es)
CN (1) CN103003269B (es)
AR (1) AR081368A1 (es)
AU (1) AU2011252223A1 (es)
BR (1) BR112012028651A2 (es)
CA (1) CA2798375A1 (es)
CO (1) CO6640218A2 (es)
CR (1) CR20120570A (es)
CU (1) CU20120157A7 (es)
DO (1) DOP2012000284A (es)
EA (1) EA201291167A1 (es)
EC (1) ECSP12012288A (es)
ES (1) ES2462522T3 (es)
IL (1) IL222851A0 (es)
MA (1) MA34939B1 (es)
MX (1) MX2012012960A (es)
PE (1) PE20130228A1 (es)
SG (1) SG185459A1 (es)
TN (1) TN2012000531A1 (es)
TW (1) TW201200510A (es)
UY (1) UY33369A (es)
WO (1) WO2011141326A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2504586C2 (ru) * 2007-05-01 2014-01-20 Хилл'С Пет Ньютришн, Инк. Способы и композиции для диагностики остеоартрита у животного семейства кошачьих
RU2009146851A (ru) * 2007-05-18 2011-06-27 Байер Шеринг Фарма Акциенгезельшафт (DE) Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
AU2011252223A1 (en) * 2010-05-08 2012-12-06 Bayer Intellectual Property Gmbh Substituted heterocyclyl benzyl pyrazoles, and use thereof
WO2014008257A2 (en) 2012-07-02 2014-01-09 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
AU2013305633B2 (en) 2012-08-24 2018-03-08 Board Of Regents, The University Of Texas System Heterocyclic modulators of HIF activity for treatment of disease
US20140073634A1 (en) * 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
WO2014031933A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
ES2726648T3 (es) 2014-02-25 2019-10-08 Univ Texas Sales de moduladores heterocíclicos de la actividad del HIF para el tratamiento de enfermedades
US10191597B2 (en) 2015-06-30 2019-01-29 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
WO2018131657A1 (ja) * 2017-01-13 2018-07-19 日産化学工業株式会社 芳香族ジアミン化合物前駆体の製造方法
CN115944626B (zh) * 2022-12-08 2024-04-19 桂林医学院附属医院 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
CN100387594C (zh) 2003-04-03 2008-05-14 麦克公司 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂
CA2530679A1 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
RU2009146851A (ru) * 2007-05-18 2011-06-27 Байер Шеринг Фарма Акциенгезельшафт (DE) Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
EP2356113B1 (de) * 2008-11-14 2015-01-07 Bayer Intellectual Property GmbH Heterocyclisch substituierte aryl-verbindungen als hif-inhibitoren
RU2011123672A (ru) * 2008-11-14 2012-12-20 Байер Шеринг Фарма Акциенгезельшафт Гетероароматические соединения для применения в качестве hif ингибиторов
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
US8389509B2 (en) 2009-01-23 2013-03-05 Bristol-Myers Squibb Company Substituted pyrazole compounds
AU2011252223A1 (en) * 2010-05-08 2012-12-06 Bayer Intellectual Property Gmbh Substituted heterocyclyl benzyl pyrazoles, and use thereof

Also Published As

Publication number Publication date
EP2569312A1 (de) 2013-03-20
CA2798375A1 (en) 2011-11-17
US8470811B2 (en) 2013-06-25
IL222851A0 (en) 2012-12-31
JP2013526497A (ja) 2013-06-24
US20120028950A1 (en) 2012-02-02
PE20130228A1 (es) 2013-03-15
AR081368A1 (es) 2012-08-29
BR112012028651A2 (pt) 2016-08-09
US20130172311A1 (en) 2013-07-04
CO6640218A2 (es) 2013-03-22
MA34939B1 (fr) 2014-03-01
TN2012000531A1 (en) 2014-04-01
ES2462522T3 (es) 2014-05-23
WO2011141326A1 (de) 2011-11-17
KR20130108997A (ko) 2013-10-07
CN103003269A (zh) 2013-03-27
ECSP12012288A (es) 2012-12-28
CU20120157A7 (es) 2013-03-27
AU2011252223A1 (en) 2012-12-06
SG185459A1 (en) 2012-12-28
CN103003269B (zh) 2015-11-25
EA201291167A1 (ru) 2013-05-30
UY33369A (es) 2011-12-01
CR20120570A (es) 2013-04-22
MX2012012960A (es) 2012-12-17
TW201200510A (en) 2012-01-01
JP5727002B2 (ja) 2015-06-03
EP2569312B1 (de) 2014-03-26

Similar Documents

Publication Publication Date Title
DOP2012000284A (es) Heterociclilbencilpirazoles sustituidos y uso de los mismos
UY32237A (es) Compuestos de arilo con sustituyentes heterociclicos y su uso
UY32236A (es) Compuestos de arilo sustituidos y su uso
GT201500105A (es) Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso
WO2012143497A3 (de) Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CU20140096A7 (es) Fenilimidazopirazoles sustituidos y su uso
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
WO2014153385A3 (en) Methods of treating metabolic disorders
EP3318879A4 (en) Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
HK1206720A1 (en) Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinsons disease taar
BR112012028652A2 (pt) hidroxialquilbenzilpirazois e seu uso
EA201490562A1 (ru) Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов
PH12015501538A1 (en) Topical ocular analgesic agents
UA112981C2 (uk) Варіант людського gdnf